GLP-1 weight-loss drugs cut heart attack and stroke risk in largest long-term review

A new Anglia Ruskin University meta-analysis covering more than 90,000 patients across 11 trials finds GLP-1 receptor agonists cut major cardiovascular events by about 13 percent compared with placebo. The benefit covers heart attack, stroke, and cardiovascular death over an aver

Anglia Ruskin GLP-1 meta-analysis cuts cardiovascular events 13 percent | Qualys discloses 9-year-old Linux kernel ptrace flaw CVE-2026-46333 ssh-keysign-pwn | Stratolaunch Talon-A3 hits Mach 5 plus for MDA in FEX-04 hypersonic test